- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04270929
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma (PANC-001)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02908
- Roger Williams Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with histologically confirmed diagnosis of adenocarcinoma of the pancreas. Patient must have either histologic confirmation of the primary tumor or metastasis.
- Patients must have locally advanced, unresectable or metastatic pancreatic adenocarcinoma.
- Patient must be between 18 - 80 years of age.
- Patient able to understand and sign informed consent.
- Patient may be chemotherapy naïve or may have failed one line of conventional therapy
Prior FOLFIRINOX therapy:
Patients who have previously received FOLFIRINOX chemotherapy for locally advanced unresectable pancreatic cancer are eligible for enrollment upon this study if they meet the following criteria-
- FOLFIRINOX chemotherapy was completed more than six months ago,
- Patients who are currently candidates for re-challenge with FOLFIRINOX chemotherapy for their recurrent cancer, and
- Patients have no persistent non-hematologic toxicity greater than grade 1 (due to prior FOLFIRINOX therapy)
Patients with metastatic cancer who are currently receiving FOLFIRINOX chemotherapy are eligible for enrollment upon this study if they meet the following criteria-
- Patients have received no more than six cycles of FOLFIRINOX chemotherapy,
- Patients have at least stable disease on imaging, and
- Patients have no persistent non-hematologic toxicity greater than grade 1 (due to ongoing FOLFIRINOX therapy)
- Patient with a life expectancy of greater than six months.
- Patient with performance status of 0 to 1 (ECOG).
All patients must have adequate organ function as defined by:
- ANC greater than or equal to 1500/mm3, platelets ≥ 100,000/mm3, Hgb ≥ to 8 g/dL; patient may be transfused to achieve Hgb ≥ 8 g/dL to satisfy enrollment criteria, or as otherwise indicated by symptoms for Hgb > 8 g/dL.
- Creatinine ≤ 1.5mg/dl or creatinine clearance ≤ 60cc/min.
- Direct bilirubin <1.5X ULN, alkaline phosphatase <5X ULN, and ALT/AST <5X ULN (ULN = upper limit of normal).
- No evidence of congestive heart failure, symptoms of coronary artery disease, serious cardiac arrhythmias, including uncontrolled atrial fibrillation/atrial flutter, evidence of prior myocardial infarction by history or EKG.
- No serious, symptomatic obstructive or emphysematous lung disease, or asthma requiring intravenous medications within the past 12 months; no serious lung disease associated with dyspnea at normal activity levels (grade III) or at rest (grade IV), due to any cause (including cancer metastases and pleural effusions).
- Acceptable vascular anatomy as determined by CT, MR, or conventional venography.
Exclusion Criteria:
- Female patients of childbearing age will be tested for pregnancy. Pregnant and breastfeeding patients will be excluded from the study. Males who are actively seeking to have children will be made aware of the unknown risks of this study protocol on human sperm and the need to practice birth control.
- Patients with serious or unstable renal, hepatic, pulmonary, cardiovascular, endocrine, rheumatologic, or allergic disease based on history, physical exam and laboratory tests will be excluded.
- Patients with uncontrolled diabetes mellitus or a history of pancreatitis.
- Patients with cholelithiasis and a history of choledocholithiasis.
- Patients with concurrent malignancies, except for cutaneous carcinomas.
- Patients with unsuitable vascular anatomy.
- Portal vein occlusion/thrombosis, history of portal hypertension, cirrhosis, hepatitis, or with radiographic evidence of cirrhosis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oxaliplatin PEDD-PRVI
Two infusions of oxaliplatin (dose escalation: 20-40 mg) over the course of 4 weeks by Pancreatic Retrograde Venous Infusion (PRVI) utilizing Pressure Enabled Drug Delivery (PEDD) technology.
|
During Cycles 1 and 2, standard of care systemic FOLFIRI will be delivered on Days 2-4 following oxaliplatin PEDD-PRVI.
During Cycles 3-6, standard of care systemic FOLFIRINOX will be administered on Days 1-3.
The TriSalus Infusion System administers therapeutics using PEDD technology.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Completion Rate of oxaliplatin PEDD-PRVI
Time Frame: 3 months
|
To determine the completion rate of oxaliplatin delivery by PEDD-PRVI as measured by the percentage of successful placements of the TriSalus Infusion System and delivery of the assigned dose of oxaliplatin regionally into the pancreas via RVI per each patient, at each dose-level, and across all enrolled patients in the study.
Successful delivery of oxaliplatin by PEDD-PRVI will be confirmed using real-time fluoroscopic guidance.
The success rate of completion of PEDD-RVI per patient and acroos all-patients will be calculated
|
3 months
|
Safety of oxaliplatin PEDD-PRVI: maximum tolerable dose (MTD)
Time Frame: 3 months
|
To determine the safety of oxaliplatin PEDD-PRVI by identifying the maximum tolerable dose (MTD).
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine local progression free survival
Time Frame: 3 months
|
Assess the time frame of pancreatic tumor stability prior to progression by radiographic imaging
|
3 months
|
To determine systemic progression free survival.
Time Frame: 3 months
|
Assess the time frame of metastatic tumor stability prior to progression by radiographic imaging
|
3 months
|
To determine overall survival
Time Frame: 3 months
|
As a measure of activity, overall survival will be assessed.
The events for the assessment of overall survival are death events.
|
3 months
|
Radiographic response rates by PET
Time Frame: 3 months
|
Changes in tumor metabolic activity
|
3 months
|
Radiographic response rate by perfusion MRI
Time Frame: 3 months
|
Changes in tumor size
|
3 months
|
Serologic response rates (CA 19-9)
Time Frame: 3 months
|
Serial measurement of serum CA 19-9 levels
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rathore, Roger Williams Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 342-30
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium
Clinical Trials on FOLFIRI
-
Biotheus Inc.RecruitingNeuroendocrine NeoplasmChina
-
Scandion Oncology A/STFS Trial Form SupportRecruitingMetastatic Colorectal CancerDenmark, Spain, Germany
-
4SC AGCompletedAdvanced Colorectal CarcinomaGermany
-
Fudan UniversityRecruitingColorectal CancerChina
-
University of SaskatchewanTerminatedMetastatic Gastro-esophageal AdenocarcinomaCanada
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Fudan UniversityUnknownColorectal CancerChina
-
The First People's Hospital of ChangzhouCompleted
-
Fujian Cancer HospitalNot yet recruitingAdvanced Colorectal Cancer
-
Repare TherapeuticsActive, not recruitingAdvanced Solid TumorUnited States, Canada, Spain, United Kingdom